Lombard Odier Asset Management Switzerland SA Boosts Stake in Abbott Laboratories $ABT

Lombard Odier Asset Management Switzerland SA increased its holdings in shares of Abbott Laboratories (NYSE:ABT) by 19.7% during the first quarter, HoldingsChannel.com reports. The fund owned 107,096 shares of the healthcare product maker’s stock after buying an additional 17,600 shares during the period. Lombard Odier Asset Management Switzerland SA’s holdings in Abbott Laboratories were worth $10,996,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Cornerstone Financial Management LLC purchased a new position in Abbott Laboratories in the 4th quarter worth approximately $25,000. MidAtlantic Capital Management Inc. purchased a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $25,000. Purpose Unlimited Inc. acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in Abbott Laboratories during the fourth quarter worth approximately $26,000. Finally, Abound Financial LLC acquired a new position in Abbott Laboratories during the fourth quarter worth $26,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analyst Ratings Changes

ABT has been the subject of several analyst reports. TD Cowen restated a “buy” rating and issued a $115.00 target price on shares of Abbott Laboratories in a report on Friday, July 17th. Robert W. Baird began coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price target on the stock. Wells Fargo & Company upped their price objective on shares of Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a report on Friday, July 17th. The Goldman Sachs Group reduced their target price on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research note on Wednesday, May 27th. Finally, Citigroup boosted their target price on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $118.61.

Abbott Laboratories Trading Up 2.4%

Shares of ABT stock opened at $103.13 on Friday. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49. The firm has a market cap of $179.63 billion, a PE ratio of 33.38, a price-to-earnings-growth ratio of 2.00 and a beta of 0.61. The company has a 50-day moving average of $91.61 and a two-hundred day moving average of $101.33. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The business had revenue of $12.51 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The business’s revenue was up 13.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, analysts predict that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is 81.55%.

Insider Buying and Selling

In other news, Director Daniel J. Starks acquired 10,000 shares of the company’s stock in a transaction dated Monday, April 27th. The stock was acquired at an average cost of $92.65 per share, with a total value of $926,500.00. Following the completion of the purchase, the director owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This represents a 0.15% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 0.46% of the stock is owned by company insiders.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.